Characterisation of the pharmacokinetic profile of amantadine in the common marmoset
Objective: To determine the pharmacokinetic (PK) profile of amantadine in the common marmoset (Callithrix jacchus). Background: Amantadine is currently approved for the treatment of L-3,4-dihydroxyphenylalanine…Decreased occurrence of dyskinesia when combining amantadine to L-DOPA in early Parkinson disease (PD): the PREMANDYSK trial
Objective: To assess amantadine effects on dyskinesia and other PD symptoms when adjunct to L-DOPA in early PD. Background: Amantadine is efficacious on L-DOPA-induced dyskinesia…Utilization pattern and factors associated with amantadine use in Parkinson’s disease (PD) of the French NS-Park cohort
Objective: To assess amantadine use in the French NS-Park cohort and factors associated with its prescription Background: Amantadine, a unique dopamine/glutamate drug, is approved worldwide…Demographic, clinical and genetic factors affecting amantadine response among patients with Parkinson disease
Objective: To identify factors that correlate with efficacy and tolerability of amantadine to predict therapeutic outcomes Background: Amantadine is the only commercially available medication to…Risk of hallucinations and amantadine treatment in levodopa-induced dyskinesia patients with Parkinson’s disease: a meta-analysis of randomized controlled trials
Objective: The present meta-analysis aims to find out association between risk of hallucinations and amantadine treatment in levodopa-induced dyskinesia (LID) patients with Parkinson’s disease (PD).…Amantadine Delayed Release/Extended Release Capsules Reduce the Proportion of the Day Spent in “BAD” Time (ON with Troublesome Dyskinesia or OFF): Analysis of Phase 3 Trial Data
Objective: To evaluate the effect of treatment with amantadine delayed release/extended release (AMT DR/ER) vs. placebo on the proportion of the waking day spent in…Amantadine Is Effective Long-term in Parkinson’s Disease
Objective: This study aimed to investigate the long-term effectiveness of amantadine in patients with PD. Background: Amantadine has been used in the symptomatic treatment of…Should Amantadine DR/ER Be Considered Prior to Device-Aided Therapies for Parkinson’s Disease?
Objective: Evaluate delayed release/extended release amantadine (AMT DR/ER) capsules for motor complications in patients meeting 5-2-1 criteria for device-aided therapies (DAT) in advanced Parkinson disease.…Amantadine DR/ER-Related Reduction in OFF and Dyskinesia Improved Patient-Rated Interference with Activities and Social Interactions
Objective: Evaluate dyskinesia and OFF interference with activities and experiences for persons with Parkinson disease (PWPD), and mitigation with treatment Background: OFF and Dyskinesia remain…Amantadine DR/ER Efficacy as Early Add-On for Motor Complications in Parkinson’s Disease
Objective: Utilize clinical trial data to analyze amantadine delayed release/extended release (AMT DR/ER) capsules as an early add-on for OFF and dyskinesia in people with…
Abstracts from the International Congress of Parkinson’s and Movement Disorders.